News + Events

News & Events

Basel Life Science Week 2015
Cydan Founder and CEO, Dr. Chris Adams will be presenting at the Jumpstarting Innovation Forum.
September 21-24, 2015
Basel, Switzerland

Ninth Annual NINDS Nonprofit Forum
Cydan Founder and CSO, Dr. James McArthur will be presenting at the Progress through Partnership Forum.
September 8-9, 2015
Bethesda, MD

2015 NF Conference
Cydan VP Preclinical Development, Dr. Aileen Healy will be on a panel titled, "Academic versus Industry Drug Discovery".
June 6-9, 2015
Monterey, CA

MassBio Conference
Cydan Founder and CSO, Dr. James McArthur will be on a panel titled, “Will Innovation & Technology "Bridge" the Gaps in Translational Medicine for Orphan Diseases?”
June 2, 2015
Cambridge, MA

Dione Kobayashi has joined the Cure Congenital Muscular Dystrophy (Cure CMD) Scientific Medical Advisory Board.
Curecmd.org
May 1, 2015

Neurotech Investing and Partnering Conference
Cydan Founder and CSO, Dr. James McArthur will be on a panel titled, “Targeting Orphan Diseases”
April 8, 2015
San Francisco, CA

m4 Technology Transfer Summit
Cydan Founder and CEO, Dr. Chris Adams will be presenting, “Accelerating Orphan Drug Opportunities”
March 22-23, 2015
Munich, Germany

Redefining Early Stage Investments (RESI) Conference
Cydan Founder and CEO, Dr. Chris Adams will be on a panel titled, “Orphan and Rare Disease Investors”
January 13, 2015
San Francisco, CA

James McArthur has joined the Friedreich's Ataxia Research Alliance (FARA) Board of Directors
curefa.org
January 1, 2015

 

 

 

Press Releases

01.06.16 | Vtesse, Inc. Announces FDA’s Granting of Breakthrough Therapy Designation for VTS-270 in Niemann-Pick Type C1 Disease

11.04.15 | Cydan Announces the Promotion of Dione Kobayashi, Ph.D., to Vice President, Preclinical Translation

09.28.15 | Vtesse, Inc. Initiates Phase 2b/3 Clinical Trial of VTS-270 for Treatment of Niemann-Pick Type C1 (NPC) Disease

06.24.15 | Cydan Announces Recipients of its MassChallenge Scholarship

03.19.15 | Cydan Supports Innovation for Patients with Rare Diseases through MassChallenge Scholarships

02.23.15 | Orphan Drug Accelerator Cydan Supports Rare Disease Day® and Joins Patients, Advocates and Massachusetts Legislators to Raise Awareness for Rare Diseases

01.07.15 | Leading Life Science Syndicate Commits $25 Million to Series A Funding to Launch Vtesse, Inc., the First Rare Disease Company Spun Out of Cydan Development, Inc.

10.15.14 | Orphan Drug Accelerator Cydan Expands Transactional Expertise with Appointment of Vered Bisker-Leib, Ph.D., MBA, as Chief Business Officer

10.01.13 | Cydan Expands Initial Financing to $26 Million; Lundbeckfond Ventures and Bay City Capital Join Diverse Investor Syndicate With Participation from NEA and Alexandria Venture Investments

07.09.13 | Kurma Life Sciences Partners and Cydan Enter Collaboration to Further Expand Global Network and Strengthen Ability to Identify New Rare Disease Assets

04.11.13 | Cydan, a New Orphan Drug Accelerator, Launches with $16 Million Financing from Leading Investors NEA, Pfizer Venture Investments and Alexandria Real Estate Equities